Premium
Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity
Author(s) -
Rachakonda Vikrant P.,
Reeves Valerie L.,
Aljammal Jules,
Wills Rachel C.,
Trybula Joy S.,
DeLany James P.,
Kienesberger Petra C.,
Kershaw Erin E.
Publication year - 2015
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.20960
Subject(s) - medicine , autotaxin , endocrinology , adipokine , steatosis , nonalcoholic fatty liver disease , fatty liver , lysophosphatidic acid , insulin resistance , obesity , disease , receptor
Objective Autotaxin (ATX) is an adipocyte‐derived lysophospholipase that generates the lipid signaling molecule lysophosphatidic acid (LPA). The aim of this study was to determine the relationship between serum ATX and nonalcoholic fatty liver disease (NAFLD) in females with obesity. Methods 101 nondiabetic women with obesity (age: 31.5‐55.8 years; BMI: 35.0‐64.5 kg/m 2 ) were classified as having NAFLD (36.3%) or not having NAFLD (63.7%) based on the degree of hepatic steatosis on abdominal CT. Subjects were characterized for metabolic phenotype including measures of energy, glucose, and lipid homeostasis. Fasting serum adipokines and inflammatory markers were determined by ELISA. Linear regression analysis was used to determine features independently associated with NAFLD. Results Subjects with and without NAFLD differed in several key features of metabolic phenotype including BMI, waist circumference, fasting glucose and insulin, HOMA‐IR, VLDL, triglycerides, and ALT. Serum adipokines, including ATX and leptin, were higher in subjects with NAFLD. Serum ATX was significantly correlated with alkaline phosphatase, fasting glucose, fasting insulin, and HOMA‐IR. Linear regression analysis revealed that serum triglycerides and log‐transformed ATX were independently associated with hepatic steatosis. Conclusions Serum ATX may be a potential pathogenic factor and/or biomarker for NAFLD in nondiabetic women with obesity.